Investigation on Differences in Skin Sodium Content Between Normal Subjects and ICU-patients

NCT ID: NCT02912299

Last Updated: 2017-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-03

Study Completion Date

2017-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the differens in sodium storage in skin between normal subjects, patients after cardiac surgery and septic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to the current paradigm ICU-acquired hypernatremia is mainly an iatrogenic problem, caused by sodium overload or water deficit. In spite of several interventions to reduce sodium intake and optimize fluid balance, critically ill patients still develop hypernatremia. These patients also seem to have an inability to excrete sodium, hence develop a positive sodium balance. In animals sodium storage in the third compartment was found. Our hypothesis is that sodium storage in the third compartment is different in critically ill patients and this difference could play a role in the development of ICU-acquired hypernatremia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypernatremia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Septic patients

Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.

Skin biopsies

Intervention Type PROCEDURE

2 3mm skin biopsies will be taken

Blood and urine analysis

Intervention Type OTHER

Measurement of sodium, potassium and kidneyfunction in blood and urine.

Blood collection for RNA-investigation

Intervention Type OTHER

A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.

CABG patients

Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.

Skin biopsies

Intervention Type PROCEDURE

2 3mm skin biopsies will be taken

Blood and urine analysis

Intervention Type OTHER

Measurement of sodium, potassium and kidneyfunction in blood and urine.

Blood collection for RNA-investigation

Intervention Type OTHER

A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.

Patients before hip replacement

Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.

Skin biopsies

Intervention Type PROCEDURE

2 3mm skin biopsies will be taken

Blood and urine analysis

Intervention Type OTHER

Measurement of sodium, potassium and kidneyfunction in blood and urine.

Blood collection for RNA-investigation

Intervention Type OTHER

A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin biopsies

2 3mm skin biopsies will be taken

Intervention Type PROCEDURE

Blood and urine analysis

Measurement of sodium, potassium and kidneyfunction in blood and urine.

Intervention Type OTHER

Blood collection for RNA-investigation

A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50-80 years (septic patients), 45-85 years (CABG and hip replacement-patients)
* Patients undergoing hip replacement: no relevant medical history (i.e. chronic and/or systemic diseases with a suspected influence on sodium / sodium handling)
* Septic patients: fulfilling the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection

Exclusion Criteria

* Absence of both upper legs
* Skin disease that makes skin biopsies in healthy skin impossible
* Subjects with in their history formation of exaggerated scar tissue
* Subjects suffering from psoriasis or lichen ruber
* Use of skin corticosteroids on all skin of both upper legs \< 2 weeks before inclusion
* Tattoos covering the whole surface of both upper legs
* Use of diuretics in the past month
* Current renal replacement therapy
* Septic patients: not being sedated
* Patients undergoing hip replacement: hip replacement because of an inflammatory disease
Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Groningen

OTHER

Sponsor Role collaborator

Frisius Medisch Centrum

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christiaan Boerma, MD PhD

Role: PRINCIPAL_INVESTIGATOR

medical center leeuwarden

Jaap van den Born, PhD

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Groningen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Polderman KH, Schreuder WO, Strack van Schijndel RJ, Thijs LG. Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med. 1999 Jun;27(6):1105-8. doi: 10.1097/00003246-199906000-00029.

Reference Type BACKGROUND
PMID: 10397213 (View on PubMed)

Waite MD, Fuhrman SA, Badawi O, Zuckerman IH, Franey CS. Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay. J Crit Care. 2013 Aug;28(4):405-12. doi: 10.1016/j.jcrc.2012.11.013. Epub 2013 Jan 29.

Reference Type BACKGROUND
PMID: 23369520 (View on PubMed)

Lee JW. Fluid and electrolyte disturbances in critically ill patients. Electrolyte Blood Press. 2010 Dec;8(2):72-81. doi: 10.5049/EBP.2010.8.2.72. Epub 2010 Dec 31.

Reference Type BACKGROUND
PMID: 21468200 (View on PubMed)

Titze J, Krause H, Hecht H, Dietsch P, Rittweger J, Lang R, Kirsch KA, Hilgers KF. Reduced osmotically inactive Na storage capacity and hypertension in the Dahl model. Am J Physiol Renal Physiol. 2002 Jul;283(1):F134-41. doi: 10.1152/ajprenal.00323.2001.

Reference Type BACKGROUND
PMID: 12060595 (View on PubMed)

Titze J, Lang R, Ilies C, Schwind KH, Kirsch KA, Dietsch P, Luft FC, Hilgers KF. Osmotically inactive skin Na+ storage in rats. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1108-17. doi: 10.1152/ajprenal.00200.2003. Epub 2003 Jul 29.

Reference Type BACKGROUND
PMID: 12888617 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL 56729.099.16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.